X4 Pharmaceuticals

111 articles with X4 Pharmaceuticals

• X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020

  4/23/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results and business highlights for the first quarter ended March 31, 2020 at 8:30 a.m. ET on May 7, 2020. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to

• X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference

  4/9/2020

  April 9, 2020 12:00 UTC X4 Pharmaceuticals to Present and Participate in the Virtual 19 th Annual Needham Healthcare Conference

• X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar

  4/7/2020

  X4 Pharmaceuticals, Inc. today hosted a virtual Analyst Day, A Deep Dive into WHIM Syndrome , the target disease of the company's Phase 3 candidate

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 1, 2020

  4/1/2020

  X4 Pharmaceuticals, Inc. announced that on March 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Host 2020 Analyst Day Webinar:A Deep Dive into WHIM Syndrome

  3/25/2020

  March 25, 2020 12:00 UTC X4 Pharmaceuticals to Host 2020 Analyst Day Webinar: A Deep Dive into WHIM Syndrome - Virtual event to be held on Tuesday, April 7, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will host a virtual Analyst Day to discuss its strateg

• X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

  3/12/2020

  X4 Pharmaceuticals, Inc. today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2020

  3/2/2020

  X4 Pharmaceuticals, Inc. announced that, on February 28, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020

  2/27/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced it will host a conference call and webcast to report its financial results for the fourth quarter and full year ended December 31, 2019 on March 12, 2020 at 8:30 a.m. ET. The conference call can be accessed by dialing (866) 721-765

• X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March

  2/25/2020

  Feb. 25, 2020 13:30 UTC X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team will present and conduct one-on-one meetings at Cowen and Company’s 40th Annual Health Care Conference and Oppenheimer's 30th Annual H

• X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor

  2/12/2020

  Feb. 12, 2020 13:00 UTC – Patent expected to provide exclusivity through 2038 – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent No. 10,548,889, which is expected to provide exclusivity of X4’s lead therapeuti

• 

  Clinical Catch-Up: December 30, 2019 – January 2, 2020

  1/6/2020

  Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.

• X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

  12/30/2019

  Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance

• X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants

  11/26/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 3,666,667 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 1,750,000 shares of common stock

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 26, 2019

  11/26/2019

  X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced that, on November 26, 2019, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Announces Proposed Public Offering

  11/25/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and Class B warrants to purchase its common stock

• X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

  11/15/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY.

• X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome

  11/12/2019

  Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM, for the treatment of WHIM syndrome.

• 

  BioSpace Movers & Shakers, Nov. 8

  11/8/2019

  Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.

• X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

  11/7/2019

  Reported positive data from Phase 2a clinical trial of mavorixafor in combination with axitinib in advanced clear cell renal cell carcinoma patients

• X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia

  11/5/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils.